Citation: Wm. Dankner et al., Correlates of opportunistic infections in children infected with the humanimmunodeficiency virus managed before highly active antiretroviral therapy, PEDIAT INF, 20(1), 2001, pp. 40-48
Authors:
Buchacz, K
Cervia, JS
Lindsey, JC
Hughes, MD
Seage, GR
Dankner, WM
Oleske, JM
Moye, J
Citation: K. Buchacz et al., Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children, PEDIATRICS, 108(4), 2001, pp. NIL_91-NIL_97
Authors:
Gortmaker, SL
Hughes, M
Cervia, J
Brady, M
Johnson, GM
Seage, GR
Song, LY
Dankner, WM
Oleske, JM
Citation: Sl. Gortmaker et al., Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1, N ENG J MED, 345(21), 2001, pp. 1522-1528
Authors:
Waecker, NJ
Stefanova, R
Cave, MD
Davis, CE
Dankner, WM
Citation: Nj. Waecker et al., Nosocomial transmission of Mycobacterium bovis bacille Calmette-Guerin to children receiving cancer therapy and to their health care providers, CLIN INF D, 30(2), 2000, pp. 356-362
Citation: Wm. Dankner et Ce. Davis, Mycobacterium bovis as a significant cause of tuberculosis in children residing along the United States-Mexico border in the Baja California region, PEDIATRICS, 105(6), 2000, pp. NIL_45-NIL_49
Authors:
Shingadia, D
Viani, RM
Yogev, R
Binns, H
Dankner, WM
Spector, SA
Chadwick, EG
Citation: D. Shingadia et al., Gastrostomy tube insertion for improvement of adherence to highly active antiretroviral therapy in pediatric patients with human immunodeficiency virus, PEDIATRICS, 105(6), 2000, pp. NIL_50-NIL_54
Authors:
Frenkel, LM
Capparelli, EV
Dankner, WM
Xu, J
Smith, IL
Ballow, A
Culnane, M
Read, JS
Thompson, M
Mohan, KM
Shaver, A
Robinson, CA
Stempien, MJ
Burchett, SK
Melvin, AJ
Borkowsky, W
Petru, A
Kovacs, A
Yogev, R
Goldsmith, J
McFarland, EJ
Spector, SA
Citation: Lm. Frenkel et al., Oral ganciclovir in children: Pharmacokinetics, safety, tolerance, and antiviral effects, J INFEC DIS, 182(6), 2000, pp. 1616-1624
Authors:
King, JC
Borkowsky, W
Mahidhara, N
Madore, D
Shapiro, ED
Rutstein, RM
Tan, TQ
Farley, JJ
Dankner, WM
Nachman, S
Simoes, E
Flynn, PM
Clemens, J
Hamilton, RG
Citation: Jc. King et al., Group-specific antibody levels surrounding invasive pneumococcal illness in children infected with human immunodeficiency virus, J INFEC DIS, 181(5), 2000, pp. 1817-1821
Authors:
Ngo, LY
Yogev, R
Dankner, WM
Hughes, WT
Burchett, S
Xu, J
Sadler, B
Unadkat, JD
Citation: Ly. Ngo et al., Pharmacokinetics of azithromycin administered alone and with atovaquone inhuman immunodeficiency virus-infected children, ANTIM AG CH, 43(6), 1999, pp. 1516-1519
Authors:
Viani, RM
Dankner, WM
Muelenaer, PA
Spector, SA
Citation: Rm. Viani et al., Resolution of HIV-associated nephrotic syndrome with highly active antiretroviral therapy delivered by gastrostomy tube, PEDIATRICS, 104(6), 1999, pp. 1394-1396
Authors:
Kline, MW
Blanchard, S
Fletcher, CV
Shenep, JL
McKinney, RE
Brundage, RC
Culnane, M
Van Dyke, RB
Dankner, WM
Kovacs, A
McDowell, JA
Hetherington, S
Citation: Mw. Kline et al., A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection, PEDIATRICS, 103(4), 1999, pp. E471-E475